Biocept Inc  

(Public, NASDAQ:BIOC)   Watch this stock  
Find more results for BIOC
-0.015 (-2.43%)
Real-time:   2:02PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.60 - 0.64
52 week 0.60 - 3.39
Open 0.63
Vol / Avg. 168,496.00/376,037.00
Mkt cap 18.60M
P/E     -
Div/yield     -
EPS -0.89
Shares 30.26M
Beta 2.90
Inst. own 18%
Nov 9, 2017
Q3 2017 Biocept Inc Earnings Call
Nov 9, 2017
Q3 2017 Biocept Inc Earnings Release
Sep 6, 2017
Biocept Inc at Liolios Group Gateway Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -523.78% -570.86%
Operating margin -516.73% -559.25%
EBITD margin - -549.25%
Return on average assets -181.19% -202.58%
Return on average equity -410.78% -845.67%
Employees 42 -
CDP Score - -


5810 Nancy Ridge Dr Ste 150
SAN DIEGO, CA 92121-2840
United States - Map
+1-858-3208200 (Phone)
+1-858-3208225 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Officers and directors

Michael W. Nall President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Timothy C. Kennedy Chief Financial Officer and Senior Vice President of Operations
Bio & Compensation  - Reuters
Lyle J. Arnold Ph. D. Senior Vice President - Research & Development, Chief Scientific Officer
Age: 69
Bio & Compensation  - Reuters
Veena Singh M.D. Senior Vice President, Senior Medical Director
Age: 41
Bio & Compensation  - Reuters
Michael Terry Senior Vice President - Commercial Operations
Bio & Compensation  - Reuters
Raaj Trivedi Vice President - Commercial Operations
Age: 43
Bio & Compensation  - Reuters
David S. Moskowitz Vice President - Strategy and Corporate Communications
Age: 53
Bio & Compensation  - Reuters
David F. Hale Non-Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Marsha A. Chandler Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Bruce E. Gerhardt CPA Independent Director
Age: 65
Bio & Compensation  - Reuters